Figure 1: The chart above illustrates the mean change in Malondialdehyde (MDA) levels after the 12-week intervention period for the placebo, melatonin, and lycopene groups:

Figure 2: This figure illustrates the mean change in Total Antioxidant Capacity (TAC) after the 12-week intervention period for the placebo, melatonin, and lycopene groups:

Figure 3: This figure illustrates the mean reduction in DNA damage, as assessed by the comet assay, after the 12-week intervention period for the placebo, melatonin, and lycopene groups:

Figure 4: This figure illustrates the mean changes in lipid profiles after the 12-week intervention period for the placebo, melatonin, and lycopene groups across key lipid categories:

Figure 5: This figure shows the mean changes in inflammatory biomarkers after the 12-week intervention period for the placebo, melatonin, and lycopene groups:

Figure 6: This figure illustrates the mean changes in symptom severity and quality of life after the 12-week intervention period for the placebo, melatonin, and lycopene groups:

Figure 7: This figure illustrates the anti-inflammatory, hypolipidemic, and mortality risk reduction effects of melatonin, lycopene, and their combination. Here's a summary of the findings: